Expression of Peroxisome Proliferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death

Neoplasia

Volumn 1, Issue 4, 1999, Pages 330-339

  Guan, You Fei ^a   Zhang, Ya Hua ^a   Breyer, Richard M ^a,c   Davis, Linda ^a   Breyer, Matthew D ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Cell proliferation; Differentiation; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ALITRETINOIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CDKN1A PROTEIN, HUMAN; CELL RECEPTOR; CHROMAN DERIVATIVE; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA; FABP7 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LIGAND; LUCIFERASE; MYELIN BASIC PROTEIN; NICOTINIC ACID DERIVATIVE; PROTEIN P16INK4A; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RIBONUCLEASE; TETRALIN DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DEATH; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; METABOLISM; PATHOLOGY; TRANSACTIVATION; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CELL DEATH; CHROMANS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID-BINDING PROTEINS; G1 PHASE; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; LIGANDS; LUCIFERASES; MYELIN P2 PROTEIN; NEOPLASM PROTEINS; NICOTINIC ACIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RIBONUCLEASES; TETRAHYDRONAPHTHALENES; THIAZOLES; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0033206336     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, Evans RM, and Spiegelman BM (1996). Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 10, 974-984.
2. Guan Y, Zhang Y, Davis L, and Breyer MD (1997). Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273, F1013-F1022.
3. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91, 7355-7359.
4. Jiang C, Ting AT, and Seed B (1998). PPARg agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
5. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997). Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272, 3406-3410.
6. Forman B, Tontonoz P, Chen J, Brun R, Spiegelman B, and Evans R (1995). 15-deoxy-12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-gamma. Cell 83, 803-812.
7. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, and Evans RM (1998). PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
8. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CDM, Brun PP, Mueller E, Altiok S, Oppenheim H, Evans RM, and Spiegelman BM (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor g and the retinoid X receptor. Proc Natl Acad Sci USA 94, 237-241.
9. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, and Spiegelman BM (1998). Terminal differentiation of human breast cancer through PPARg. Mol Cell 1, 465-470.
10. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, and Koeffler HP (1998). Ligands for peroxisome proliferator-activated receptor g and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer in vitro and in BNX mice. Proc Natl Acad Sci USA 95, 8806-8811.
11. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, and Lazar MA (1998). The nuclear eicosanoid receptor, PPARg, is aberrantly expressed in colonic cancers. Carcinogenesis 19, 49-53.
12. Brockman JA, Gupta RA, and DuBois RN (1998). Activation of PPARg leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115, 1049-1055.
13. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, and Reddy JK (1998). Differential expression of the peroxisome proliferator-activated receptor g (PPARg) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 153, 349-354.
14. Farman N, Pradelles P, and Bonvalet JP (1987). PGE2, PGF2a, 6-keto-PGE1a, and TxB2 synthesis along the rabbit nephron. Am J Physiol 252, F53-F59.
15. 9,12-dihydroprostaglandin D2 in human urine. J Biol Chem 263, 16619-16625.
16. Danon A, Zenser TV, Thomasson DL, and Davis BB (1986). Eicosanoid synthesis by cultured human urothelial cells: potential role in bladder cancer. Cancer Res 46, 5676-5681.
17. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, and Faxon D (1996). Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest 98, 1897-1905.
18. Celis JE, Stergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Rntoft TF, and Rasmussen HH (1996). Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 56, 4782-4790.
19. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992). Convergence of 9-cis-RA and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771-774.
20. Schulman IG, Shao G, and Heyman RA (1998). Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor g (PPARg) heterodimers: intermolecular synergy requires only the PPARg hormone-dependent activation function. Mol Cell Biol 18, 3489-3494.
21. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, and Spiegelman BM (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma [see comments]. Nat Med 4, 1046-1052.
22. Elbrecht A, Chen Y, Cullinan C, Hayes N, Leibowitz M, Moller D, and Berger J (1996). Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors g1 and g2. Biochem Biophys Res Commun 224, 431-437.
23. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813-819.
24. Young MA, Eckland DJA, Eastmond R, and Lettis S (1998). Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Ann Med 30, 206-212.
25. Kubuta T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, and Koeffler HP (1998). Ligand for peroxisome proliferator-activated receptor g (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58, 3344-3352.
26. Mukherjee R, Davies PJ, Crombier DL, Bischoff ED, Cesario RM, Jow L, Hamanns LG, Boehm MF, Mondon CE, Nadzan AM, Patemiti JR, Jr, and Heyman RA (1997). Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407-414.
27. Trump D (1994). Retinoids in bladder, testis, and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 8 (suppl 3), S50-S54.
28. Sporn M, Squire R, Brown C, and Smith J (1977). 13-cis-RA: inhibition of bladder carcinogenesis in the rat. Science 195, 487-489.
29. Lamm D, Riggs D, Shriver J, vanGilder P, Rach J, and DeHaven J (1994). Megadose vitamins in bladder cancer: a double blind clinical trial. J Urol 151, 21-26.
30. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, and Sporn MB (1994). Prevention of breast cancer in the rat with 9-cis-RA as a single agent and in combination with tamoxifen. Cancer Res 54, 4614-4617.
31. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, and Heyman RA (1996). Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56, 5566-5570.
32. Gromova I, Gromov P, Wolf H, and Celis JE (1998). Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlated in non-invasive and invasive bladder transitional cell carcinomas. Int J Oncol 13, 379-383.
33. Madsen P, Rasmussen HH, Leffers H, Honore B, and Celis JE (1992). Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty-acid binding protein [PA-FABP]) that is highly up-regulated in psoriasis skin and that shares similarity to fatty-acid binding proteins. J Invest Dermatol 99, 299-305.
34. Huynh HT, Larsson C, Narod S, and Pollak M (1995). Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55, 2225-2231.
35. Yang Y, Spitzer E, Kenney N, Zschiesche W, Li M, Kromminga A, Muller T, Spener F, Lezius A, Veerkamp JH, Smith GH, Salomon DS, and Grosse R (1994). Members of the fatty acid binding protein family are differentiation factors for the mammary gland. J Cell Biol 127, 1097-1109.